Apogee Therapeutics, Inc.
APGE
$39.94
$1.614.20%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 49.01M | 41.55M | 35.82M | 29.84M | 24.58M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 216.87M | 178.14M | 143.76M | 118.53M | 93.00M |
Operating Income | -216.87M | -178.14M | -143.76M | -118.53M | -93.00M |
Income Before Tax | -182.13M | -146.66M | -118.49M | -103.55M | -83.99M |
Income Tax Expenses | 18.00K | -- | -- | -- | -- |
Earnings from Continuing Operations | -182.15 | -146.66 | -118.49 | -103.55 | -83.99 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -182.15M | -146.66M | -118.49M | -103.55M | -83.99M |
EBIT | -216.87M | -178.14M | -143.76M | -118.53M | -93.00M |
EBITDA | -216.68M | -140.88M | -82.24M | -38.15M | -- |
EPS Basic | -3.28 | -2.76 | -2.40 | -5.58 | -7.44 |
Normalized Basic EPS | -2.05 | -1.72 | -1.50 | -3.49 | -4.65 |
EPS Diluted | -3.28 | -2.76 | -2.40 | -5.58 | -7.44 |
Normalized Diluted EPS | -2.05 | -1.72 | -1.50 | -3.49 | -4.65 |
Average Basic Shares Outstanding | 220.75M | 211.89M | 196.33M | 144.81M | 99.63M |
Average Diluted Shares Outstanding | 220.75M | 211.89M | 196.33M | 144.81M | 99.63M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |